<DOC>
	<DOCNO>NCT00001909</DOCNO>
	<brief_summary>Asthma chronic inflammatory disorder airway characterize reversible airflow obstruction . Fourteen million person ( 6.4 % ) United States report asthma , 1980 1994 prevalence self-reported asthma United States increase 75 % . A major factor pathogenesis asthma development allergic inflammatory response inhale antigen . Interleukin-4 ( IL-4 ) play key role response promote IgE production , upregulating IgE receptor , upregulating adhesion receptor VCAM-1 , promote Th2 cell development increase mucus secretion . Soluble recombinantly produce IL-4R ( sIL-4R ) show bind inactivate IL-4 , vitro animal model . As part multicenter trial , 20 subject NIH site receive 0.9 mg. , 1.8 mg. sIL-4R placebo weekly 12 week double blind placebo control study . Study drug deliver via AERx aerosol drug delivery device . The primary objective study evaluate efficacy measure FEV1 . Secondary objective include change FVC , FEF 27-75 , peak flow , bronchodilator usage , asthma symptom , quality life score , immunologic inflammatory marker , pharmacokinetics , safety immunogenicity . The study population consist moderate severe asthmatic ( Beta ) -agonist monotherapy FEV1 50-80 % predict . After 12 week study drug , subject follow additional 8 week .</brief_summary>
	<brief_title>Phase II Efficacy Study Aerosolized Recombinant Human IL-4 Receptor Asthma</brief_title>
	<detailed_description>Asthma chronic inflammatory disorder airway characterize reversible airflow obstruction . Fourteen million person ( 6.4 % ) United States report asthma , 1980 1994 prevalence self-reported asthma United States increase 75 % . A major factor pathogenesis asthma development allergic inflammatory response inhale antigen . Interleukin-4 ( IL-4 ) play key role response promote IgE production , upregulating IgE receptor , upregulating adhesion receptor VCAM-1 , promote Th2 cell development increase mucus secretion . Soluble recombinantly produce IL-4R ( sIL-4R ) show bind inactivate IL-4 , vitro animal model . As part multicenter trial , 20 subject NIH site receive 0.9 mg. , 1.8 mg. sIL-4R placebo weekly 12 week double blind placebo control study . Study drug deliver via AERx aerosol drug delivery device . The primary objective study evaluate efficacy measure FEV1 . Secondary objective include change FVC , FEF 27-75 , peak flow , bronchodilator usage , asthma symptom , quality life score , immunologic inflammatory marker , pharmacokinetics , safety immunogenicity . The study population consist moderate severe asthmatic ( Beta ) -agonist monotherapy FEV1 50-80 % predict . After 12 week study drug , subject follow additional 8 week .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Interleukin-4</mesh_term>
	<criteria>Male nonpregnant , nonbreastfeeding female age 1285 year . Diagnosis persistent asthma great 1 year currently treat short act beta2 agonist . FEV1 5080 % predict ( must demonstrate Day 10 Day 0 ) . Patients stratified 5070 % 7180 % cohort Day 10 . Increase great equal 15 % baseline FEV1 approximately 1520 minute beta2 agonist inhalation ( 24 puff albuterol via MDI nebulized equivalent ) document baseline . Positive prick skin test least two allergen ( define wheal 3 mm great control erythema great control ) . History asthma symptom ( wheeze , shortness breath , cough , chest tightness , nighttime awaken ) least 3 last 7 day . Fulfillment washout criterion use medication list specified time prior Day 0 study drug treatment : Parenteral corticosteroid 4 week ; Oral corticosteroids 4 week ; Inhaled corticosteroids 4 week ; Cromolyn sodium ( Intal ) , nedocromil ( Tilade ) 4 week ; Theophylline , zileuton ( Zyflo ) , zafirlukast ( Accolate ) , montelukast ( Singulair ) 4 week ; Astemizole ( Hismanal ) 12 week ; Terfenadine ( Seldane ) , fexofenadine ( Allegra ) 6 day ; Cetirizine ( Zyrtec ) 6 day ; Hydroxyzine ( Atarax , Vistaril ) 6 day ; Azelastine ( Astelin ) nasal spray 6 day ; Salmeterol ( Serevent ) 9 day . No clinically significant abnormality chemistry , hematology , urinalysis : serum creatinine less equal 1.7 mg/dL ; total bilirubin less equal 1.5 mg/dL ; AST ( SGOT ) , ALT ( SGPT ) less equal 2 time laboratory 's upper limit normal . No clinically significant abnormality EKG within 1 month prior enrollment . No clinically significant abnormality CXR ( change consistent asthma ) within 1 year prior enrollment . Nonsmoker , least 2 year smoke history 10 pack year ( e.g. , one pack per day 10 year ) . Agreement use medically accept contraception throughout study , sexually active , except female postmenopausal great equal 2 year . Agreement donate blood blood product throughout study . Demonstrated ability follow proper technique use AERx system . A write , sign , witnessed consent form . No desensitization therapy within 3 month prior Day 0 study drug treatment . No use investigational nonapproved drug therapy within 30 day prior Day 0 study drug treatment . No occurrence acute asthma exacerbation require emergency room treatment within 6 week Day 0 study drug treatment . No occurrence acute asthma exacerbation require hospitalization within 12 month Day 0 study drug treatment . No occurrence respiratory infection affect asthma within 4 week prior Day 0 study drug treatment . No history endotracheal intubation asthmarelated exacerbation within 15 year prior Day 0 study drug treatment . No presence significant medical condition ( include obesity affect respiratory function , congestive heart failure , myocardial infarction , unstable angina , uncontrolled hypertension , severe pulmonary disease , history cancer [ resect cutaneous basal squamous cell carcinoma ] , insulindependent diabetes , autoimmune disease , know HIV infection ) . No previous enrollment study soluble IL4 receptor . No history alcohol abuse , drug abuse , psychiatric illness would interfere ability comply protocol requirement give informed consent . No patient experience hypersensitivity soluble IL4R .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1999</verification_date>
	<keyword>Allergy</keyword>
	<keyword>Immunomodulator</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Interleukin</keyword>
	<keyword>Th2</keyword>
	<keyword>Asthma</keyword>
</DOC>